Ticagrelor versus Prasugrel in acute coronary syndrome: sex-specific analysis from the RENAMI Registry
Minerva Cardiol Angiol
The use of potent P2Y12 inhibitors (ticagrelor & prasugrel) in acute coronary syndrome (ACS) patients undergoing percutaneous coronary interventions (PCI) is a class I recommendation. We performed a sex-specific analysis comparing the difference in efficacy and safety outcomes between ticagrelor and prasugrel in a real-world ACS population.
Reference
Ticagrelor versus Prasugrel in acute coronary syndrome: sex-specific analysis from the RENAMI Registry. Al Raisi S, Protty M, Raposeiras-Roubín S, D'Ascenzo F, Abu-Assi E, Ariza-Solé A, Manzano-Fernández S, Templin C, Velicki L, Xanthopoulou I, Cerrato E, Quadri G, Rognoni A, Boccuzzi G, Montabone A, Taha S, Durante A, Gili S, Magnani G, Autelli M, Grosso A, Flores-Blanco P, Varbella F, Cespón-Fernández M, Gallo D, Morbiducci U, Dominguez-Rodriguez A, Cequier A, Gaita F, Alexopoulos D, Valgimigli M, Íñiguez-Romo A, Kinnaird T. Minerva Cardiol Angiol. 2021 Jun 17. doi: 10.23736/S2724-5683.21.05591-5